Exclusive Summary

• Fluoxetine is a cornerstone first-line treatment for depression, listed on the WHO Model List of Essential Medicines with exceptionally high clinical recognition.
• With over 280 million depression patients globally, the 20mg × 14/28 capsules packaging perfectly matches the mainstream 2-4 week prescription cycles, bringing massive rigid terminal demand.
• Since the originator's patent expired years ago, overseas distributors can quickly access hospital and pharmacy channels for monetization without extra market education costs.
• Leveraging the scale advantage of China's mature supply chain, this product offers ultimate cost controls, providing generous profit margins for distributors in local public tenders and retail markets.